Literature DB >> 16077176

Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia.

Katy Wong1, Shawn Tsuda, Ryan Mukai, Kenneth Sumida, Richard Arakaki.   

Abstract

Ectopic PTH secretion by tumor cells has been described as the cause of hypercalcemia associated with malignancy in the absence of osteolytic bone lesions. Although there have been case reports of elevated PTH and hypercalcemia in patients with rhabdomyosarcoma, to date ectopic PTH secretion by malignant cells has not been definitively shown. The possibility of PTH production by pleural-based metastatic nasopharyngeal rhabdomyosarcoma cells in a 62-yr-old Japanese male with hypercalcemia was investigated. The patient's serum PTH level was found to be elevated at 62.22 pmol/L, and pleural fluid PTH level was 47.28 pmol/L and PTHrP level was 3.7 pmol/L. RT-PCR of mRNA extracted from rhabdomyosarcoma cells in the pleural fluid was performed with the addition of PTH and PTHrP exonic primer sets yielded only a cDNA fragment of approx 150 bp consistent with the expected PTH fragment. Sequence analysis of a nested primer PCR fragment confirmed PTH mRNA sequence. We believe this patient to have had hypercalcemia secondary to ectopic PTH secretion, as we have identified the presence of PTH mRNA in tumor cells. We speculate that the overexpression of PTH in rhabdomyosarcoma cells results from molecular rearrangement of the PTH gene. The finding of a normal PTH DNA sequence of the PCR fragment suggests the likelihood of alterations in regulatory sequences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16077176     DOI: 10.1385/ENDO:27:1:083

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  14 in total

Review 1.  Hypercalcemia of malignancy.

Authors:  V Grill; T J Martin
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone.

Authors:  S R Nussbaum; R D Gaz; A Arnold
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

3.  Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy.

Authors:  M Mangin; A C Webb; B E Dreyer; J T Posillico; K Ikeda; E C Weir; A F Stewart; N H Bander; L Milstone; D E Barton
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

4.  Nucleotide sequence of cloned cDNAs encoding human preproparathyroid hormone.

Authors:  G N Hendy; H M Kronenberg; J T Potts; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

5.  Elevated parathyroid hormone levels in association with rhabdomyosarcoma.

Authors:  R J Hutchinson; S A Shapiro; R B Raney
Journal:  J Pediatr       Date:  1978-05       Impact factor: 4.406

6.  Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia.

Authors:  K Yoshimoto; R Yamasaki; H Sakai; U Tezuka; M Takahashi; M Iizuka; T Sekiya; S Saito
Journal:  J Clin Endocrinol Metab       Date:  1989-05       Impact factor: 5.958

7.  Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland.

Authors:  H Iguchi; C Miyagi; K Tomita; S Kawauchi; Y Nozuka; M Tsuneyoshi; H Wakasugi
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

8.  Hypercalcemia and elevated serum parathyroid hormone level in association with rhabdomyosarcoma.

Authors:  I Elomaa; V P Lehto; R K Selander
Journal:  Arch Pathol Lab Med       Date:  1984-09       Impact factor: 5.534

9.  Nucleotide sequence of the human parathyroid hormone gene.

Authors:  T J Vasicek; B E McDevitt; M W Freeman; B J Fennick; G N Hendy; J T Potts; A Rich; H M Kronenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

10.  A thymoma as a cause of true ectopic hyperparathyroidism.

Authors:  R Rizzoli; J C Pache; L Didierjean; A Bürger; J P Bonjour
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more
  7 in total

1.  Is the risk of primary hyperparathyroidism increased in patients with untreated breast cancer?

Authors:  V Belardi; E Fiore; E Giustarini; I Muller; S Sabatini; V Rosellini; E Seregni; R Agresti; C Marcocci; P Vitti; C Giani
Journal:  J Endocrinol Invest       Date:  2012-08-29       Impact factor: 4.256

2.  Ectopic secretion of parathyroid hormone in a neuroendocrine tumor: a case report and review of the literature.

Authors:  Emad Kandil; Salem Noureldine; Mohamed Abdel Khalek; Philip Daroca; Paul Friedlander
Journal:  Int J Clin Exp Med       Date:  2011-09-15

Review 3.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

4.  An unusual case of malignancy-related hypercalcemia.

Authors:  Mary-Anne Doyle; Janine C Malcolm
Journal:  Int J Gen Med       Date:  2013-12-06

Review 5.  Hypercalcemia of malignancy and new treatment options.

Authors:  Hillel Sternlicht; Ilya G Glezerman
Journal:  Ther Clin Risk Manag       Date:  2015-12-04       Impact factor: 2.423

6.  Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies.

Authors:  Cheng Cheng; Jose Kuzhively; Sanford Baim
Journal:  Case Rep Endocrinol       Date:  2017-01-12

7.  An Excess of CYP24A1, Lack of CaSR, and a Novel lncRNA Near the PTH Gene Characterize an Ectopic PTH-Producing Tumor.

Authors:  Kosuke Uchida; Yuji Tanaka; Hitoshi Ichikawa; Masato Watanabe; Sachiyo Mitani; Koji Morita; Hiroko Fujii; Mayumi Ishikawa; Gen Yoshino; Hiroko Okinaga; Genta Nagae; Hiroyuki Aburatani; Yoshifumi Ikeda; Takao Susa; Mimi Tamamori-Adachi; Toshio Fukusato; Hiroshi Uozaki; Tomoki Okazaki; Masayoshi Iizuka
Journal:  J Endocr Soc       Date:  2017-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.